FindTrial
Sign In

Assessing how well the heart works in cancer patients receiving cancer treatment using advanced Heart scan.

Myocardial function Assessment using 3D Echocardiography in Cancer patients undergoing Immunotherapy or Targeted Therapy-A Cohort Study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/063271
Enrollment
184
Registered
2024-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Ananya P Raj
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cancer Patients of 18-80 years of age who are undergoing Targeted therapy or Immunotherapy

Exclusion criteria

Exclusion criteria: Pre-existing heart disease Pre-existing Hypertension Suboptimal window Valvular heart disease which is more than mild in severity Renal dysfunction

Design outcomes

Primary

MeasureTime frame
3D EF (in %), Global strain LV, RV (in %), TAPSE (in cm) and PA pressure (in mmHg), Ejection fraction (in %), Diastolic function – E and A (in m/s), Volumes at end diastole and systole (in ml) – LV, Tissue doppler imaging (TDI) of septum and lateral wall (in m/s), LV MPI, RV MPI, RV FAC (%), RV-PA Coupling ratio and RVOT (Prox and Distal diameter) (in mm)Timepoint: 3 and 6 Months—

Secondary

MeasureTime frame
Cardiac arrhythmia, Major Adverse Cardiac Events (MACE) and HypertensionTimepoint: 3 and 6 months—

Countries

India

Contacts

Public ContactAnanya P Raj

Manipal College Of Health Professions

ananya6.mchpmpl2022@learner.manipal.edu8152856160

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026